Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Designed to address emerging areas of patient need, including long-term weight management, co-morbid metabolic disorders, and muscle preservation during weight loss
Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. ('Nxera'; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders.
Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline across a broad range of validated GPCR targets in these major disorders.
Chris Cargill, President and CEO of Nxera, commented: 'Nxera scientists were among the pioneers in elucidating the structure of the GLP-1 receptor and other key receptors being targeted, giving us a clear advantage in developing potentially best-in-class next generation drug candidates. For the past 12 months, Nxera scientists have been advancing a broad metabolic disease pipeline to capitalize independently on our differentiated science. Today, we reveal the addition of these programs to our discovery portfolio, and are confident in achieving significant progress over the mid-term, delivering clear value for shareholders and patients in the rapidly expanding obesity market, projected to exceed US$100 billion annually in global sales.'
Central to Nxera's pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from Pfizer's PF-06954522, allowing Nxera full control to drive rapid progress.
Complementing this program, Nxera is simultaneously accelerating the advancement of an additional six established GPCR-targeted programs focused on obesity and chronic weight management: Three small molecule agonist programs (GIP, Apelin, Amylin)
One small molecule antagonist program (GIP)
Two long-acting programs (targets undisclosed)
Nxera's pipeline leverages its proprietary NxWave™ GPCR-focused structure-based design platform to rapidly identify unique, highly differentiated lead molecules with novel chemistry. This process utilizes Nxera's NxHit proprietary small molecule libraries and NxStaR proteins for DNA encoded library (DEL) screening, distinguishing these candidates from others currently in discovery and clinical development globally.
Nxera's focused approach is designed to deliver highly effective therapies addressing critical patient needs: Long-term weight maintenance: Convenient, scalable oral therapies for sustained weight loss.
Convenient, scalable oral therapies for sustained weight loss. Targeting key obesity-related co-morbidities: Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously.
Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously. Reducing side effects and broadening out to difficult to treat populations: Targeted treatments for elderly, post-menopausal, and sarcopenic populations.
Backed by an expert team with deep experience in GPCR drug discovery, Nxera is strategically positioned to be a leader in developing the next generation of best-in-class obesity and metabolic therapies.
Nxera maintains its strong commitment to other key therapeutic areas including neurology, gastroenterology, and immunology, continuing to leverage the NxWave™ platform's proven capabilities in these domains.
Separately, Nxera notes that Pfizer yesterday discontinued development of its Phase 1 candidate PF-06954522, a separate small molecule GLP-1 agonist, which was discovered under a strategic drug discovery collaboration with Nxera. This discontinuation by Pfizer was due to a portfolio decision and not because of any adverse safety findings. Nxera intends to enter discussions with Pfizer regarding potential opportunities to advance GLP-1 molecules discovered by Pfizer under the collaboration.
Nxera will announce its earnings results and present operational highlights for Q2 2025 on Friday, 8 August 2025.
–END–
About Nxera Pharma
Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally.
We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region.
Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation.
Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).
For more information, please visit www.nxera.life
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma
Enquiries:
Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager
+81 (0)3 5962 5718 | +44 (0)1223 949390 |[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
23 minutes ago
- Business Upturn
Robert F. Kennedy Jr. cancels $500 million in mRNA vaccine projects
By Bhavya Rai Published on August 6, 2025, 14:39 EDT Health Secretary Robert F. Kennedy Jr. has announced that the government will cancel $500 million worth of vaccine development projects. These projects were based on mRNA technology, the same kind used in COVID-19 vaccines by Pfizer and Moderna. Kennedy said this decision came after a full review of the science and discussions with top health experts. Kennedy explained that the Department of Health and Human Services believes mRNA vaccines bring more risks than benefits, especially for diseases like COVID-19 and the flu. He shared the news in a video on the social media platform X. Kennedy has long been critical of vaccines, so this move was not a surprise to many. The cancellation affects 22 different projects. Major pharmaceutical companies like Pfizer, Sanofi, and CSL Seqirus will lose funding. Some universities, including Emory and Tiba Biotech, will also have their projects stopped. Only a few projects in their final stages will be allowed to finish. Many health experts are worried about this decision. Rick Bright, a former government vaccine expert, said it's a big mistake. He believes cutting mRNA research makes the country less prepared for future pandemics. He also said the decision could harm national security. The government also said that BARDA, the agency that supports vaccine research, will stop funding any new mRNA projects. Instead, they will invest in other vaccine types, such as whole-virus vaccines or newer methods. Some mRNA work in other areas of medicine may still continue. This is a major change in how the U.S. handles vaccine research. Many people are now wondering what this means for the future of pandemic response and public health.
Yahoo
27 minutes ago
- Yahoo
Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Pfizer and other large pharmaceutical companies are taking seriously President Donald Trump's demand that drugmakers make more of their medicines available direct to consumers in the U.S. at lower cost, Pfizer CEO Albert Bourla said Tuesday. 'We have serious discussions in the industry,' Bourla told investors on a conference call Pfizer held to discuss its earnings for the second quarter. 'I'm connected very often individually with all the major companies and they are all ready to roll up their sleeves and execute something like that.' Pfizer and partner Bristol Myers Squibb recently announced plans to offer their widely-used blood thinner Eliquis at a discounted cash price through an online service. The company previously launched a direct-to-consumer service that allows patients to book telehealth appointments, schedule vaccinations and fill prescriptions for certain medicines, such as those Pfizer sells for migraine and COVID-19. 'We think it is a fantastic way to go ahead, so we will work collaboratively to do it,' Bourla said. Obesity drugmakers Eli Lilly and Novo Nordisk have also recently opened up more ways for cash-paying patients to access their weight loss medicines directly. Other companies are signaling interest, too, in exploring ways to sidestep pharmacy benefit managers. These drug-purchasing middlemen extract from drugmakers rebates that insurers say they use to lower overall costs, but not necessarily in ways that are obvious to a prescription-filling patient. Expanding direct-to-consumer options was one of four demands Trump made of the pharmaceutical industry last week in letters issued to 17 drugmakers, including Pfizer. In those letters, the president threatened to use 'every tool' the U.S. government has available if the companies don't take steps to lower the cost of their products to the prices paid in other industrialized countries. Such a 'most favored nation' policy could be a major blow to the industry, although analysts are divided on how sweeping its impact would be if limited only to Medicaid, as Trump indicated. On Tuesday's call, Bourla said he is in 'active discussions' at the 'highest levels of the U.S. government,' including conversations with Trump, Health and Human Services Secretary Robert F. Kennedy Jr., and Centers for Medicare and Medicaid Services Administrator Mehmet Oz. In addition to leading Pfizer, Bourla is the current board chair of industry lobbying group PhRMA. 'The letter asks a lot from us,' Bourla added. 'But we are engaged in productive discussion with them and in general I'm happy with the way that they listen to us.' Pricing threats aren't the only challenge drugmakers face in the U.S. The Commerce Department is nearing the end of an investigation into pharmaceutical imports expected to result in sector-specific tariffs. On Tuesday, Trump told CNBC that his administration will initially impose a small levy on pharmaceuticals that could later rise as high as 250% over time. Such duties would be costly for drugmakers, but analysts believe a phase-in period would allow many companies to adjust their supply chains in such a way that the worst financial hit could be mitigated. Already, most of the largest drugmakers have announced major manufacturing investments in the U.S. Pfizer anticipates that it can absorb the impact of tariffs this year, as well as any changes it makes to its products' prices, while still meeting its financial forecast of $61 billion to $64 billion in revenue. On Tuesday, the company raised its guidance for adjusted diluted earnings per share by 10 cents. Shares in Pfizer rose by nearly 4% by midday Tuesday. Recommended Reading Trump redoubles threats in attempt to strongarm drugmakers on prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
33 minutes ago
- Business Wire
EnerSys Announces $1 Billion Increase to Stock Repurchase Authorization and 9% Dividend Increase
READING, Pa.--(BUSINESS WIRE)-- EnerSys (NYSE: ENS), a global leader in stored energy solutions announced today that its Board of Directors has approved a $1 billion increase to its stock repurchase authorization, to be executed over the next five years. This authorization brings the Company's total outstanding repurchase authorization to an aggregate of $1.06 billion, including $58 million available under the Board's previous repurchase authorizations. Additionally, the Company announced that its Board of Directors has raised its quarterly cash dividend for the third consecutive year, with an increase of 9% to $0.2625 per share of common stock. The dividend is payable on September 26, 2025, to holders of record as of September 12, 2025. 'These announcements highlight EnerSys' proactive and disciplined approach to capital allocation and our confidence in our long-term strategy,' said Shawn O'Connell, EnerSys President and Chief Executive Officer. 'Our earnings growth, strong cash flow, and solid balance sheet enable us to continue investing in long-term growth while returning more capital to shareholders. The increased stock repurchase authorization reflects our belief in the value of the Company and our growth trajectory. At the same time, we are committed to maintaining a competitive dividend that grows with our earnings, excluding the effects of 45X benefits. During this period of macro uncertainty, we intend to keep our leverage below the low end of our target range, retaining a prudent level of dry powder for future capital allocation optionality.' The authorized repurchases shall be made from time to time in either the open market or through privately negotiated transactions. The timing, volume and nature of share repurchases will be at the sole discretion of management, dependent on market conditions, applicable securities laws, and other factors, and may be suspended or discontinued at any time. No assurance can be given that any particular amount of common stock will be repurchased. All or part of the repurchases may be implemented under a Rule 10b5-1 trading plan, which would allow repurchases under pre-set terms at times when EnerSys might otherwise be prevented from doing so under insider trading laws or because of self-imposed blackout periods. This repurchase program shall be in effect for a period of five years from its adoption unless otherwise modified or terminated by the Board. About EnerSys EnerSys is a global leader in stored energy solutions for industrial applications and designs, manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories and outdoor equipment enclosure solutions to customers worldwide. The company goes to market through four lines of business: Energy Systems, Motive Power, Specialty and New Ventures. Energy Systems, which combine power conversion, power distribution, energy storage, and enclosures, are used in the telecommunication, broadband, and utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Motive power batteries and chargers are utilized in electric forklift trucks and other industrial electric powered vehicles. Specialty batteries are used in aerospace and defense applications, portable power solutions for soldiers in the field, large over-the-road trucks, premium automotive, medical and security systems applications. New Ventures provides energy storage and management systems for various applications including demand charge reduction, utility back-up power, and dynamic fast charging for electric vehicles. EnerSys also provides aftermarket and customer support services to its customers in over 100 countries through its sales and manufacturing locations around the world. To learn more about EnerSys please visit Caution Concerning Forward-Looking Statements This press release, and oral statements made regarding the subjects of this release, contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, or the Reform Act, which may include, but are not limited to, statements regarding EnerSys' earnings estimates, intention to return capital to stockholders, plans, objectives, expectations and intentions and other statements contained in this press release that are not historical facts, including statements identified by words such as 'believe,' 'plan,' 'seek,' 'expect,' 'intend,' 'estimate,' 'anticipate,' 'will,' and similar expressions. All statements addressing operating performance, events, or developments that EnerSys expects or anticipates will occur in the future, including statements relating to sales growth, continuing to pay cash dividends at the current rate, earnings or earnings per share growth, its intention to pay quarterly cash dividends and return capital to stockholders, execution of its stock repurchase program, and market share, as well as statements expressing optimism or pessimism about future operating results or benefits from either its cash dividend or its stock repurchase programs, are forward-looking statements within the meaning of the Reform Act. The forward-looking statements are based on management's current views and assumptions regarding future events and operating performance, and are inherently subject to significant business, economic, and competitive uncertainties and contingencies and changes in circumstances, many of which are beyond EnerSys' control. The statements in this press release are made as of the date of this press release, even if subsequently made available by EnerSys on its website or otherwise. EnerSys does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. Although EnerSys does not make forward-looking statements unless it believes it has a reasonable basis for doing so, EnerSys cannot guarantee their accuracy. For a list of other factors which could affect EnerSys' results, including earnings estimates, see EnerSys' filings with the Securities and Exchange Commission, including 'Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations,' and 'Forward-Looking Statements,' set forth in EnerSys' Annual Report on Form 10-K for the fiscal year ended March 31, 2025. The foregoing factors, among others, could cause actual results to differ materially from those described in these forward-looking statements. No undue reliance should be placed on any forward-looking statements.
